Helex
Helex develops precise genomic medicines to treat genetic kidney diseases with an emphasis on safety and targeted delivery. The company combines its EPIC-Cure™ 3D genome drug design platform with CRISPR-based gene editing and a proprietary kidney‑tropic lipid nanoparticle (LNP) delivery system to generate and deliver therapy-specific guide RNAs. Helex applies bioinformatics, AI/ML, and comprehensive impact estimation to optimize guide selection and minimize off-target editing during preclinical candidate selection. The company is an early preclinical biotechnology developer focused on mutation-agnostic, potential one‑time therapies for renal indications such as Autosomal Dominant Polycystic Kidney Disease.
Helex
Helex develops precise genomic medicines to treat genetic kidney diseases with an emphasis on safety and targeted delivery. The company combines its EPIC-Cure™ 3D genome drug design platform with CRISPR-based gene editing and a proprietary kidney‑tropic lipid nanoparticle (LNP) delivery system to generate and deliver therapy-specific guide RNAs. Helex applies bioinformatics, AI/ML, and comprehensive impact estimation to optimize guide selection and minimize off-target editing during preclinical candidate selection. The company is an early preclinical biotechnology developer focused on mutation-agnostic, potential one‑time therapies for renal indications such as Autosomal Dominant Polycystic Kidney Disease.